Research Article
Prognostic Impact of Tumor Budding on Moroccan Colon Cancer Patients
Table 2
Patient demographics, pathological, and molecular features.
| | Characteristics | Total (%) |
| | Age | | ≤57 | 53 (53.0%) | | ≥57 | 47 (47.0%) | | Gender | | Female | 43 (43.0%) | | Male | 57 (57.0%) | | Tumor site | | Right colon | 38 (38.0%) | | Left colon | 62 (62.0%) | | Histological subtype | | Adenocarcinoma | 86 (86.0%) | | Mucinous adenocarcinoma | 9 (9.0%) | | Others | 5 (5.0%) | | Histological grade | | Well | 46 (46.0%) | | Moderate | 46 (46.0%) | | Poor | 8 (8.0%) | | Venous invasion | | Presence | 20 (20.4%) | | Absence | 78 (79.6%) | | Perineural invasion | | Presence | 15 (15.3%) | | Absence | 83 (84.7%) | | Number of removed lymph nodes | | Mean (±SD) | 20.8 (±10.8) | | <12 | 12 (12.4%) | | ≥12 | 85 (87.6%) | | Range | 1–57 | | Positive lymph node | | Mean (±SD) | 1.3 (±2.9) | | Presence | 32 (8.6%) | | Absence | 66 (32.7%) | | Average | 0.1–16 | | Lymph node ratio | | Mean (±SD) | 0.1 (±0.14) | | Range | 0.01–0.81 | | Distant metastases (M) | | M0 | 83 (83.8%) | | M1 | 16 (16.2%) | | Disease stages | | I | 4 (4.2%) | | II | 51 (53.1%) | | III | 25 (26.0%) | | IV | 16 (16.7%) | | Treatment | | Surgery | 50 (50.0%) | | Surgery + adjuvant chemotherapy | 46 (46.0%) | | Neoadjuvant therapy | 4 (4.0%) | | Follow-up time (months) | | Mean (SD) | 49.4 (±29.3) | | Range | 6–119 | | Recurrence | | (+) | 29 (29.3%) | | (−) | 70 (70.7%) | | Recurrence patterns | | Liver | 5 (17.4%) | | Lung | 6 (20.7%) | | Peritoneum | 7 (24.1%) | | Local recurrence | 9 (31.0%) | | Others | 2 (6.8%) | | Mortality | | Death cases | 18 (18.2%) | | Censored cases | 81 (81.8%) | | MSI status | | MSS | 79 (79.0%) | | MSI | 21 (21.0%) | | KRAS mutation | | Presence | 31 (40.3%) | | Absence | 46 (59.7%) | | NRAS mutation | | Presence | 2 (2.6%) | | Absence | 75 (97.4%) |
|
|
